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Abstract
SINGLE NUCLEOTIDE POLYMORPMSMS IN THE FOLYLPOLY- GAMMAGLUTAMATE SYNTHETASE GENE
By Nadine Thompson, B .S.
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.
Virginia Commonwealth University, 2006.
Major Director: Richard G. Moran, Ph.D.
Professor, Pharmacology and Toxicology

Folic acid is an essential vitamin utilized in the one-carbon metabolism pathway for the
synthesis of purine and thymidine nucleotides, which are necessary for cell growth and
proliferation. As a result, the enzymes that participate in the metabolism of folic acid
have been good targets for cancer chemotherapy. Folylpoly-y-glutamate synthetase
(FPGS) is an enzyme in the folate metabolism pathway that catalyzes the addition of
glutamic acid to the naturally occurring folates, thereby allowing the retention of folate
cofactors in cells. Similarly, in the case of cancer chemotherapy, antifolates, such as
Lometrexol and Tomudex are retained in cells through the activity of FPGS.
Consequently, any single nucleotide polymorphisms (SNPs) that exist in the f i g s gene
may decrease or increase the cytotoxicity of antifolates and, ultimately, the clinical
response rate to antifolate therapy. The goal of this project is to define the position and
frequency of single nucleotide polymorphisms (SNPs) in the mRNA made from the f i g s
gene from peripheral blood of one hundred normal individuals. Six Polymerase Chain
Reaction (PCR) primers were designed to amplify the gene as three overlapping pieces
and four primers were designed for sequencing of the three PCR products. In this study,
we found polymorphic sites at nucleotides 64, 123, 253, 423, 1334 and 1781.

The

majority of the samples (49188) expressed mRNA with point mutations on at least one
allele at base 64, while 8 samples had a SNP at base 123. At nucleotide 123, 6 samples
expressed the heterozygote GIA genotype, and one sample expressed the homozygote
A/A allele at this site. At nucleotide 423, two samples expressed a G allele and also the
common C allele. While the SNPs at nucleotide 64, 123, and 423 caused a silent or
conservative mutation in the gene, in sample 82, a mutation C253T produced an amino
acid change from an arginine to tryptophan, which may cause a functional change in the
fpgs protein, due to the significant change in size and charge of the wild type amino acid.
Similarly, sample 26 expessed a homozygote TIT allele at nucleotide 1334 instead of the
common CIC allele expressed in the remaining samples. This point mutation caused a
valine to alanine amino acid change. We also detected a SNP that is expressed after the
stop codon in sample 40.

Chapter 1

INTRODUCTION:
Single Nucleotide Polymorphisms
Single Nucleotide Polymorphisms (SNPs) are point mutations that exist within the
genetic code of every individual (1). The four nucleotides, adenine (A), thymine (T),
guanine (G), and cytosine (C), serve as the building blocks for the DNA sequence coding
for the RNA message during transcription. A Single Nucleotide Polymorphism occurs
when one nucleotide, such as adenine for example, is replaced by another nucleotide such
as thymine, guanine or cytosine. This change in the DNA sequence may appear on one or
both alleles of a gene, producing a homozygous (altered sequence of both alleles) or
heterozygous (altered sequence of one allele) mutation. As one can imagine, a significant
change in the sequence of a gene that alters the protein sequence encoded by the RNA,
ultimately affects protein size andfor function, which can have dramatic effect on cellular
activity and function. Since all amino acids are coded by more than one codon, it is
possible to have a SNP that creates a new codon that translates to the same amino acid.
For instance, the nucleotide triplets AAA and AAG both result in insertion of a glutarnic
acid to a growing peptide codon. This 'silent' substitution normally occurs with a single
base change in the third position of the codon. In some instances, however, a base
change in the third position may cause a nonconservative change, where one amino acid
replaces another amino acid with dissimilar chemical characteristics. For instance,
mutation of the triplet, TGT to TGG would change the encoded amino acid from cysteine
to tryptophan. Similarly, base changes in the first and second position of the codon can

result in several types of different mutations. A nonsense mutation occurs when a SNP
causes an amino acid change that results in a stop codon. A missense mutation, on the
other hand, occurs when a SNP results in the replacement of an amino acid by one of
similar chemical nature, which does not alter protein function. For example, mutation of
the nucleotide triplet GAC to GAA would cause an amino change from aspartic acid to
glutarnic acid. This phenomenon, of amino acid substitution and protein function
modification, is particularly important in disease diagnosis and drug therapy, where a
point mutation may signify a disease state or may alter protein function in a way that
enables cells to become resistant or insensitive to certain drugs. It is difficult to
determine the number of single nucleotide polyrnorphisms that exist in each gene within
the human population, information that would require a complete sequence analysis of
the entire human genome across the entire human population. In fact, the complete
sequence of the entire genome of a single individual has only recently been completed

(2). Surprisingly, the human genome consists only of about 30,000 genes spanning 23
pairs of chromosomes, far below the original estimates of 150,000-250,000 (3). This
number is surprisingly low when compared to the number of genes found in species that
are much less complex than humans. The genome of C. elegans, for example, consists of
19,099 genes while D. melanogaster and S. cerevisiae have only 13,061 and 6,034 genes,
respectively (3). The estimated number of genes for M. musculus is roughly the same as
in humans (2).

It appears that the mechanism by which the human body maintains it

complexity with a limited number of genes involves gene splicing, gene rearrangement,
andtor expression of multiple transcriptional start sites that allows one gene to code for
multiple proteins or multiple forms of one protein performing entirely different functions.

Multiple transcriptional start sites in the folypoly-y-glutamate synthetase gene, for
example, allows the transcription of two forms of FPGS mRNA corresponding to two
isoforms of the FPGS enzyme (4) (See Figure 1).

SNPs in the genes of folate metabolism
The folylpolyglutamate synthetase enzyme (FPGS) plays a central role in intracellular
accumulation of folate and antifolate in the cytosolic and mitochondrial compartments of
the cell (5). Two translational start sites, one for the mitochondrial FPGS and the other
for the cytosolic FPGS, exist within thefigs coding region, allowing the gene to code for
two proteins that function in two different compartments (cytosol and mitochondria) of
the cell. The cytosolic and mitochondnal proteins are extremely important for cell growth
and survival, and so as one can imagine, if a single nucleotide polymorphism exists in an
essential part of the coding region of thefpgs gene preventing correct translation of the
mitochondnal or cytosolic protein, then cell death could occur. Recent studies have also
shown a variation in the frequency of single nucleotide polymorphisms across different
populations of people (4).

For example, the methylenetetrahydrofolate reductase

(MTHFR) gene was shown to have several polymorphic sites that appear more frequently
in certain populations of people. A C+T polymorphism at nucleotide 677 of the mt&
gene caused a change of the alanine to a valine amino acid, while an A+C
polymorphism at nucleotide 1298 caused a change in sequence from alanine to glutamate
at this site (7). While only 1 percent of the Black population in the United States, subSaharan Africa, and South America, for example, expressed the TT genotype of mthfi; 20
percent of US Hispanics, Colombians, and Amerindians in Brazil expressed this genotype

(8). Polymorphisms at nucleotide 1298 in mthfr are fairly common. White populations in

Europe, North America, and Australia showed 8-20 percent expression of the TT
genotype for the mthfr gene, and 12 percent of the Japanese were homozygous for this
allele (8). Another important protein of folate metabolism, 5-methyltetrahydrofolatehomocysteine methyltransferase (mtr), expressed an A 3 G polymorphism at nucleotide
2756 in codon 919, which caused the replacement of aspartic acid with glycine, changing
the function of this enzyme, and ultimately causing a decrease in plasma homocysteine
level (9). This residue occurs in the substrate-binding region of the protein. A small
percentage (2-3) of Japanese, Chinese, and Korean populations expressed the GG
genotype at the mtr gene, while, in the African-American population, six percent had the

GG genotype. Of Canadian Caucasian children and their mothers and in the Caucasian
population in Hawaii, 10-1 1 percent were GG homozygotes at nucleotide 2756 in the mtr
locus (10). Findings from studies such as these that analyze genetic variation across
different populations of people are necessary to understand why a certain population is
more suscemble to certain diseases and how these patients will react to varying degrees
of drug therapies. In the case of the methylenetetrahydrofolate reductase (mthfl gene, for
example, it was found, that heterozygotes expressing the C+T variant at nucleotide 677
on one chromosome have 10 percent lower red cell folate levels compared with CC
homozygotes, and TT homozygotes produced 18 percent lower red cell folate levels (11).
Individuals expressing the TT genotype also had lowered vitamin B12and plasma folate
levels. In the case of the MTR protein, where the A/G polymorphism at position 2756
replaces aspartic acid with glycine in the protein substrate-bindingregion, studies show a
lowered plasma homocysteine level in individuals expressing the GG allele than those

expressing the more frequent A allele. Another study found that individuals expressing
the GG genotype in the mtr gene appear to produce significantly higher plasma folate
levels, than those expressing the AA genotype (12). Variation in expression levels of
different proteins, especially those targeted for drug therapy, can affect the efficiency of
drug interaction with their target proteins.

Enzymes of the Folate Metabolism
There are currently a number of different chemotherapy drugs on the market that target
several proteins in the folate metabolism pathway. This pathway consists of a series of
one-carbon transfer reactions that result in the production of purine and thymidine
nucleotides necessary for DNA synthesis, amino acid metabolism, and the formation of
the methyl-donating agent, S-adenosylmethionine (SAM) (See Figure 2) (8). Once
folates are absorbed from the diet in the gastrointestinal tract, they pass through the liver
and blood stream. Folates then cross the cellular membrane through an active carriermediated transport system, which binds reduced folate compounds. There are two forms
of carrier-mediated transport system utilized by the cell for intracellular transport of
reduced folates. The first is the low affinity reduced folate carrier, which has affinity
constants in the micromolar range for its endogenous substrates 5-methyltetrahydrofolate,

5-formyltetrahydrofolate, and the antifolate, methotrexate (13). The second transporter
system employs a folate-binding protein, called the human folate receptor (hFR), which is
associated with the outer membrane of the cell (14). This system has a much higher
affinity for reduced folates, with affinity constants in the nanomolar range. Once folic
acid enters the cell, it is reduced to dihydrofolate, which is then reduced to

tetrahydrofolate (THF) through the catalytic activity of the enzyme, dihydrofolate
reductase (See Figure 2). Another reduced form of folates, 10-formyltetrahydrofolate,
serves as the donor of the single carbon group in the de novo biosynthesis of purine
nucleotides. Intracellular retention of folates in the cells occurs through the catalytic
activity of the enzyme, folylpolyglutamate synthetase (FPGS).
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The 5,10 methyleneTHF then undergoes two separate

enzymatic reactions. In the first reaction, 5,10 methyleneTHF is reduced to 5-methylTHF by methylene tetrahydrofolate reductase (MTHFR), subsequently allowing the
transfer of the N-5 methyl group from 5-methyl-THF to homocysteine, which results in
the synthesis of methionine. Methionine synthesis requires the coenzyme vitamin B-12,
the acceptor of the methyl group from 5-methyl-THF, and the enzyme methionine
synthase. Once methionine is synthesized, it converts to S-adenosylmethionine (SAM),
which serves as a source of a methyl group during DNA methylation and other
methyltransferases reactions.

The second enzymatic reaction involving the 5,10

methylenem cofactor results in the synthesis of thymidylate by the enzyme
thymidylate synthase. In this reaction, 5,10 methyleneTHF serves as the donor of the CH2
unit, which is passed to the 5&position of deoxyuridylate and reduced in the thymidylate
synthase reaction. Thus, thyrnidylate synthase functions as the enzyme that catalyzes the
transformation reaction of

2'-deoxyuridine-5-monophosphate

( d m ) to

2'-

deoxythymidine-5'-monophosphate (TMP) which is then phosphorylated by cellular
kinases and integrated into DNA. Thymidylate synthetase also causes the oxidation of
5,10 methylenem to dihydrofolate, which must then be converted back to

tetrahydrofolate by DHFR. These one-carbon transfer reactions of the folate metabolism
pathway are all required for cell growth, and, hence, this pathway is a good target for
antiproliferative drug therapy.

Inhibitors of Folate Metabolism

Antifolates are folate analogs that inhibit various points of the folate metabolism
pathway.

Some of the classical antifolates, which are inhibitors of dihydrofolate

reductase and thymidylate synthetase, are methotrexate, pemetrexed, and tomudex (See
Figure 3) (15).

Methotrexate, a competitive reversible inhibitor of Qhydrofolate

reductase, differs from folic acid in that an amino group is substituted for the hydroxyl
group at the 4' position of the pteridine ring. This structural change increases the
binding affinity of the drug to the folate-binding pocket of DHFR, making it more
dificult to displace the drug from the enzyme (16). Binding methotrexate to
dihydrofolate reductase causes a decrease in the intracellular reduced folate pools and an
increase in dihydrofolate. The retention of methotrexate inside the cell is due to activity
of folylpolyglutamate synthetase, which attaches up to six glutamate molecules to the
pteridine ring of the antifolate, causing a net trapping effect of the drug inside the cell.
Tomudex, another antifolate, is a selective inhibitor of thymidylate synthetase (TS) (17).
Tomudex, which interferes with the enzymatic activity of thymidylate synthetase, causing
a decrease in thymidylate production and DNA synthesis, and is currently being used in
therapy of colorectal cancer (17). Pemetrexed is also a potent inhibitor of thymidylate
synthetase and DHFR that accumulates inside the tumor and is retained intracellularly as
a result of polyglutamation by folylpolyglutamate synthetase (18).

Folate and Antifolate Polyglutamation
Reduced folates bind more tightly to their corresponding enzymes when in a
polyglutamated state than in a monoglutarnated state (15). Similarly, the binding affinity
of antifolates to their target enzymes increases, as they are polyglutamated by FPGS. The
structure of the FPGS enzyme with its folate and antifolate binding sites is illustrated in
Figure 4. Consequently, as these drugs are retained inside the cells, their cytoxicity is
prolonged and their ability to inhibit cell growth and proliferation improves. Furthermore,
previous studies have shown that tumor cells that have partially inactivating mutations in
FPGS are resistant to most antifolates (19). For these reasons, FPGS plays central role in
trapping of intracellular antifolates, and is viewed as critical to the efficacy of antifolate
chemotherapy.

Folylpolyglutamate Synthase

Human folylpolyglutamate synthetase gene is located on human chromosome 9q34 (20).
The rnRNA consists of 2475 base pairs spliced from 15 exons and the entire gene spans
11.2 kb of genomic DNA (21).

FPGS cDNA isolated from T-acute lymphocytic

leukemia cells (CEM) encodes a protein with 545 amino acids that has a MW of 60 Kd.
The transcription of the humanfigs gene results in the production of two separate mRNA
variants that code for a cytosolic and a mitochondnal isoform of the FPGS protein (4).
The cytosolic isoform has a shorter N-terminus than the mitochondrial isoforrn, and lacks
the upstream mitochondnal leader sequence found in the mitochondrial isoform.

The

transcriptional leader sequence of the mitochondrial construct allows the transport of

FPGS protein to the mitochondnal matrix compartment of the cell, where FPGS is
required for mitochondnal folate accumulation.
Accumulation of folates inside the cytosolic and mitochondria1 compartments of the cell
allows for the survival and maturation of proliferating cells. Any significant mutation in
the fpgs gene might prevent intracellular accumulation of folates, which affects cell
growth and cell survival. In the case of antifolate drugs, a mutation in thefpgs gene will
negatively impact proteiddrug interactions, thereby preventing intracellular accumulation
of the antifolates (19).

Previous reports of SNPs in the humanfpgs gene
There are currently a number of single nucleotide polymorphisms in the figs gene that
have been reported in the NCBI SNP database. The NCBI SNP database, which was
established by the National Human Genome Research Institute and the National Center
for Biotechnology Information, is a readily accessible repository of single nucleotide
polymorphisms from genes that have been sequenced worldwide. The genetic
polyrnorphisms (including nucleotide substitutions, deletion, and insertions) that have
been submitted to the SNP database come from random sequencing performed manually
or robotically in different laboratories. Because many of these randomly submitted SNPs
have not yet been confirmed by further studies, it is difficult to distinguish true SNPs
from sequencing errors. Table 2 is a compilation of all 37 unique SNPs that have been
submitted to the NCBI database since July 2006. Of the 38 SNPs submitted, 27 of them
were detected in the introns and 8 were detected in the exons of the gene. While two of
the SNPs submitted were never detected on the figs locus by Blast search, four of the

intronic SNPs were from unknown regions of the intron. Of the 8 exonic SNPs reported,
four were detected in exon 15, one in exon 16, one in exon 11, and two were detected in
exon 1. Three of the SNPs detected in exon 15 were from the 3'untranslated region
(UTR) of the gene. Only two of these SNPs, located in the 3'untranslated region of the
Jigs locus, were later confirmed in other studies. SNP entry # rs4451422 was later
confirmed in a study performed on 354 samples. The heterozygote A/C allele and the
homozygote A/A and C/C alleles were detected at a frequency ratio of .065 1.234/ .333
respectively. The remaining .367 allelic frequencies were unspecified in the Database
(see NCBI Database). SNP entry # rs10 106 was also later confirmed in a study conducted
using 421 samples. The heterozygote AIG allele and the homozygote A/A and G/G
alleles were detected at a frequency ratio of .48 1.22 / .30 respectively. The remaining
SNP, founded in exon 15 (entry # rs12686275), which caused an amino acid changed
from valine to aspartic acid was never confirmed in a study done using 209 samples. For
this reason, SNP entry # rs12686275 appears to be the result of an error in the sequence.
Similarly, SNP entry number rs1042304, of uknown intron, was checked in a study done
using 204 samples and was never detected. This SNP also seems to be a sequencing error.
Of the three SNPs detected in exon I, SNP entry # rs17855899 and # rs10760502, found
in codon 22 and which caused an isolucine to valine amino acid change, was submitted
two times to the NCBI database. This SNP was later detected in 55% of the samples used
in this study. SNP entry #rs2230270 of exon 11 that resulted in a threonine to alanine
amino acid conversion has also been confirmed by a study done using 23 samples. The
alleles detected from this study were homozygote A/A and heterozygote A/G at a
frequency of 95.7% and 4.3% respectively. Entry # rs11554717 was another SNP that

was detected in exon 1 of codon 2 1. This SNP caused an A to C polymorphism, which
did not change the glycine amino acid of the protein. This SNP has not yet been
confirmed. Similarly, SNP # rs17855900, which caused a C to T polymorphism that
changed the valine to an alanine and has not yet been confirmed. Both these unconfirmed
SNPs appeared as a result of random sequencing. The intronic SNPs that have been
confirmed are entry # rs7856096 and rs955171. SNP rs7856096 was confirmed in a
study performed on 209 indviduals. In this study the alleles detected were A/A, A/G,
and GG at a frequency ratio of .885 / .091 / .024 respectively. Similarly, SNP rs955171
was confirmed in four studies. Three of these studies had 100% C/Cs in all 30 samples
while the other study had 100% G/G in all 47 samples. Reasons for the discrepancy in
these two results are unknown.
In the current experiment, we have detected a number of single nucleotide
polymorphisms in thefpgs gene that may cause significant functional differences in the
FPGS protein. The first portion of these experiments involves the isolation of RNA using
the Trizol method and sequencing of PCR products from three control cell lines with a

known polymorphic site at nucleotide 64 in exon 1 of the gene. The next portion of the
experiment involves isolation of RNA from 100 patient samples using the Quiagen
method, which we found to be less time consuming, and direct sequencing of the PCR
products to determine the presence of polymorphisms. For the 100 patient samples, RNA
integrity and concentration was determined using the microchip on the Agilant
Bioanalyzer. Sequencing was done at the DNA core lab at the Virginia Commonwealth
University and at the SeqWright and Fisher Scientific Laboratory, and single nucleotide
polymorphisms were detected using the Codoncode Aligner computer program. All

polymorphisms presented have been confirmed through repeated experiments across a
number of different samples.

Fig 1. Transcriptional start site for human fpgs
The entire humanfpgs mRNA construct consisting of 2487 nucleotides is displayed in
Figure 1. Two translational methionine start sites (as shown in blue, along with the stop
codon) were detected in this region of the human&gs mRNA by PCR-derived RACE (4).
The first methionine site signals the initiation of translation of the leader sequence of the
mitochondrial F'PGS protein, while the second methionine site signals the start of
translation of the cyosolic F'PGS enzyme. The 3' untranslated region of the mRNA
construct consists of 50 nucleotides and the 5' untranslated region consists of 673
nucleotides. The mitochondria1 fpgs mRNA consists of 1765 nucleotides and the
cytosolicfpgs mRNA consists of 1643 nucleotides of the coding (21). These data were
reproduced fiom GenBank entry N M 003056 (www.ncbi.gov).
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1561 cccacccacc cacawtgc agtgccagct ccctcgtctt cagctgcatt tcacatgcct
1621tgaatggat cagccaaggc cgagacccca tctbxagcc acctagtccc ccaaagggcc
1681 tcctcaccca ccctgtggct cacagtgggg ccagcatact ccgtgaggct gctgccatcc
1741 atgtgctagt cactggcagc ctgcacctgg tgggtggtgt cctgaagctg ctggagcccg
ccwmm@ m g g a g
ctgcctgcgt
1801cactgtcccagtas1861 tctccccatg aactlmxh ctaggtgcct mgmttg gctttcctgg ttctgtctag
1921 wtggcctag gggccagsc wggw3g !!Pggccggga gaggatgtct mttaaggc
1981 tctgtgcctt ggtctctcct tcctcttggc tgagatagca gaggggctcc ccgggtctct
204 1 cactgttgca gtggcctggc cgttcagcct g t c t c c m acaccccgcc tgcctcctgg
2101 ctcaggccca gcttattgtg tgcgctgcct ggccaggccc tgggtcttgc catgtgctgg
agggcctctg cctgggacac
2 161 gtggtagatt tcctcctccc agtgccttct -gag
222 1 tgca-g
aI3gegctg &agtgaatta ~~Wst a a s w w
228 1 ccttcgactg acccttgacc ccctgctccc tcagcagaga cggagggagg ggctgctggt
2341 $5f@c4zggac ctgcactgtg tagagggagc cQsa3wg g c d m w240 1 ctccctgtgc gcctcaggtg gcctgtctgt gagatgagaa gaagaccaga ctgaagcctg
2461 ttmaaatat gccaggcagt gcmct

-

-

Fig. 1

Fig 2. Folate Metabolism Pathway
Folic Acid is utilized in the folate metabolism pathway, which consists of a series of onecarbon transfer reactions that result in DNA synthesis and DNA methylation. Folic acid
enters the folate metabolism pathway as its reduced form, dihydrofolate, which ultimately
reduces to 5,lO-methyltetrahydrofolatethrough the enzyme 5,lO-methyltetrahydrofolate
reductase. 5,lO-methyltetrahydrofolate then enters the thymidylate synthase pathway
where it plays a central role in the conversion of deoxyuridine monophosphate to
deoxythymidine monophosphate in the synthesis of purine and thymidine nucleotides.
Similarly, 5-methyltetrahydrofolate (a reduced form of tetrahydrofolate) plays a central
role in the formation of the methyl donating agent, S-adenosylmethionine (SAM) in the

DNA methylation pathway. This diagram was moQfied from Sharp, L et a1 (6).
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Fig 3. Classical Antifolates
Three classical antifolates used for cancer chemotherapy are methotrexate, pemetrexed,
and tomudex. Due to their structural similarities to folates, these folate analogs serve as
effective inhibitors of folate metabolism. Methotrexate is a competitive reversible
inhibitor of dihydrofolate reductase, whose increased binding affinity to dihydrofolate
reductase causes a decrease in the intracellular reduced folate pools. Similarly, tomudex
when bound to thymidylate synthase, inhibits its enzymatic activity, thereby decreasing
thymidylate production and DNA synthesis.

Pemetrexed, also an antifolate that is

structurally similary to folic acid, inhibits both thymidylate synthase and dihydrofolate
reductase, preventing DNA and RNA synthesis (15).

Tomudex

Pemetrexed

Fig. 3

Fig 4. Ribbon structure of the Lactobacillus casei FPGS enzyme

In order to fully understand the clinical significance of SNPs in the fpgs gene and its
effect on antifolate therapy, extensive research on the structure of the FPGS enzyme must
be conducted. The position at which amino acid changes occur in the polypeptide chain
determines the degree by which they would affect the enzymatic activity of the protein.
An amino change in the active site, for example, would greatly affect the catalytic
activity of the enzyme versus an amino change on the outer surface of the enzyme.
Figure 4 illustrates the ribbon structure of the Lactobacillus casei FPGS enzyme. The
blue a.rea of the structure represents the N-terminal of the FPGS protein, which is
composed of a ras-like domain and a three-stranded P-sheet (shown in green) (22). The Cterminal of the enzyme, which appears to contain the folate-binding cavity, is illustrated
by red portion of the structure. The ATP-binding P-loop motif of the enzyme is
highlighted in magenta, and next to the ATP-binding P-loop motif lies the fl loop, which
serves as the active site of the enzyme, and is highlighted in cyan. Thin black lines
represent the joining of the breaks in the polypeptide chain, and the alph-helix A10 of the
enzyme is highlighted in pink (22).

Pig. 4

Chapter 2
MATERIALS AND METHODS
Cell Line and Culture
Three human tumor cell lines, CEM (lymphoblastic leukemia cells), MCF-7 (breast
cancer cells), and WIDR (colon carcinoma cells) were grown in RPMI-1640 medium
supplemented with 10% fetal bovine serum and maintained at 37" in 5% C02 Cell counts
were determined using tryptan blue and a hemocytometer.

RNA Isolation: Control Samples
RNA from three control cell lines, CEM, MCF-7, and WIDR, was extracted using Trizol
reagents from Invitrogen Life Technologies. In a 15 ml tube, Trizol was added to cell
pellets at a ratio of lml of Trizol 1 1.4 x lo7 cells and the cell suspension was vortexed for
1 minute to homogenize the cells and extract the nucleic acids. The mixture was then
incubated for 3 minutes at room temperature and 0.2 ml of chloroform/lml of Trizol was
added. The mixture was vortexed for 15 seconds, and incubated for 15 minutes at room
temperature. The samples were then centrifuged at 12,000 g for 15 minutes and the
aqueous phase was transferred to a new Eppendorf tube. Isopropanol was added and the
tubes were centrifuged at full speed in a Beckman microfuge for 10 minutes at 4 ' ~ .Each
cell pellet was then washed with 500 p1 of 70% ethanol and the suspension was
centrifuged at full speed for 2 minutes in a cold room. The pellet was air dned for 10
minutes and then dissolved in 50 p1 of diethyl pyrocarbonate (DEPC) water. The RNA
concentration and RNA purity were estimated by spectrophotometry (using a Spectronic
Genesys 5 spectrophotometer), by adding 5 p1 of sample and + 95 p1 Tris-EDTA buffer

(TE) and determining the absorbancy at 260 nm and 280 nm. RNA concentration was

determined using the Beer-Lambert law which state that A=

E

C1 (A=Absorbancy at a

particular wavelenth, E = Extinction coefficient, C =Concentration and 1 = path length of
spectrophotometer cuvette in centimeters). An A260reading of 1.0 is equivalent to 40
pg/yl of RNA. An aliquot (1 pl of the 50 p1 solution) of each RNA sample was then run
on a 1% denaturing agarose gel to assess RNA integrity.

RNA Isolation: Patient Samples
Samples of peripheral blood were obtained from Carleton Garrett, M.D, Catherine
Dumur, PhD and Amy Ladd, PhD, of the Molecular Diagnostics Laboratory of Virginia
Commonwealth University. Ail samples were drawn with informed consent and were
supplied for this study anonymously by Carleton Garrett, M.D. Peripheral blood was
collected from 100 normal patients and mononuclear cells (MNC) were isolated using the
Ficoll-Paque Plus technique. RNA was extracted from the cell pellets using the Qiagen
RNAse easy kit and following the protocol suggested by the manufacturer. Cells were
lysed using 350 p1 of Buffer RLT, a buffer containing guanidinium isothiocyanate and 13mercaptoethanol, and the cell suspension was vortexed until no cell clumps remained in
the sample. The lysate was then washed using 350 p1 of 70% ethanol to ensure sufficient
RNA binding to an RNeasy silica-gel membrane of the mini column (used as a device to
remove RNA contaminants). Following washing of the lysate with ethanol, 700 p1 of
sample was then added to the RNeasy mini column and the mini column was centrifuged
for 15 seconds at 12,000 rpm.

To remove contaminants from the RNA, additional

washing of the RNA on the mini column was done using 700 p1 of RWl and 500 pI of
Buffer RPE and the mini column was centrifuged for 15 seconds at 12,000 rpm after each
addition. The columns were then removed and placed in a collection tube and the mini

column was then centrifuged for 2 min at maximum speed to dry the membrane. For
complete elution of the RNA from the columns, 25 p1 RNase-free water was applied
directly to the filter of the column, let stand for 5 minutes at room temperature and
centrifugation at 12,000 rpm for 1 minute. An aliquot (1 p1) of Rnase irhbitor was added
to each sample to prevent RNA degradation. The RNA concentration and RNA purity
was estimated by spectrophotometry by adding 5 ul of sample and + 95 p1 TE and
determining absorbancy at 260 nrn and 280 nm.

Quantification of RNA and Assaying RNA Integrity

To assess the integrity of total RNA, lul from each sample was loaded and ran on a chip
of the Agilent 2100 Bioanalyzer.

The Agilent 2100 Bioanalyzer produces an

electropherogram that displays two peaks corresponding to the 18s and 28s ribosomal
RNAs that one usually observes on denaturing agarose gel (See Figure 6). We were able
to determine the intemty of the RNA based on the height and quality of peaks
representing the 18s and 28s ribosomal RNA displayed by the Agilent 2 100 Bioanalyzer.
Two distinct peaks appearing on the electropherogram represent pure RNA while
multiple small peaks represent RNA degredation.
First-strand cDNA Synthesis

First-strand cDNA synthesis was done using the Invitrogen Superscript I1 kit. Two
reaction mixtures were prepared in a 0.5 ml tube. The first reaction mixture (RNARrimer
mix) consists of total RNA template (3 ug), random hexamers (.2 ug), lOmM
deoxyribonucleotide triphosphates (cLNTPs), plus an added volume of nuclease-fiee water
to achieve total desired RNA concentration. This mixture was then incubated at 65OC for

5 minutes and chilled on ice for at least lminute. The second mixture (cDNA synthesis
mix) consisted of 2 p1 of lox RT Buffer (consisting of 0.5 M Tris-HC1 , 0.75 M KC1,

0.03 M MgC12), 4 p1 of 25 mM MgC12,2 pl o f . 1 M DTT, and 1pl RNaseOUT (4U / pl).
An aloquot of the cDNA synthesis mixture (9 p1) was then added to each tube of
RNA/Primer mix and the tubes were gently mixed, briefly centrifuged, and incubated at
2 5 ' ~for 2 minutes. A 1p1 aliquot of Superscript 11 (200 units) was then added to each
tube, and the tubes incubation at 2 5 ' ~for 8 minutes. RNA mixtures are then incubated at
5 0 ' ~for 50 minutes to activate the reverse transcriptase enzyme and begin reverse
transcribing RNA to cDNA, then the reactions were terminated at 7 0 ' ~for 5 minutes to
inactivate the enzyme. The tubes were then chilled on ice. Reactions were then collected
by brief centrifugation, followed by the addition of 1 p1 of E. coli Rnase H to each tube
and the tubes were incubated at 3 7 ' ~for 20 minutes. The cDNA synthesis reaction mixes
were then stored at - 2 0 ' ~until use in the Polymerase Chain Reaction.

Polymerase Chain Reaction (Control samples)
DNA from the three control samples, CEM, MCF-7, and WIDR, was amplified using the
Polymerase Chain Reaction as two separate fragments using four primers. Due to the
high GC rich region of the 5' UTR region of the fpgs gene (cctugugcgc tgccgggggc
gccgggact), which complicates the specificity of primer binQng, amplification of the
gene as a single 1.8 kb fragment was not feasible. As an alternative, the entire coding
region of the fpgs gene was amplified as two overlapping PCR fragments (See Figure 6).
Two primers were designed for amplification of the first fragment (.8 kb fragment) and
another set of primers were designed for the second fragment (1 kb fragment). Reagents
used per 25 pl reactions were 2.5X Enhancer and 2.5X Buffer solution from InVitrogen

Life Technologies, 2 mM MgS04, 1 uM primer, an aliquot dimethyl sulfoxide, 1 unit of
Taq DNA Polymerase, .2 mM dNTPs, 2.5 units of Pfu DNA Polymerase, 2 p1 of cDNA,
and 13.5 p1 of HPLC water.

PCR condition were set at 94°C for 30 seconds

(denaturing), 37 - 72°C for 30 seconds (annealing), 72°C for 30 seconds (synthesis), 35
cycles only, 72°C for 5 minutes (final elongation) followed by 4°C storage.

Polymerase Chain Reaction (patient samples)
Optimum PCR condition for the first fragment was performed using primers FOR3 and
REVSEQ8OO (See Figure 11) at 94°C for 30 seconds, 52°C for 30 seconds, 72°C for 30
seconds, 35 cycles only, 72°C for 5 minutes, followed by 4°C storage. For the second
fragment PCR was performed using primers FORNEW and REVNEW at 94°C for 30
seconds, 55°C for 30 seconds, 72°C for 30 seconds, 35 cycles, 72°C for 5 minutes,
followed by 4OC for precipitation. For the third fragment PCR was performed using
primers FPGS RP2 and RP2. PCR conditions were set at 94OC for 30 seconds, 60°C for
30 seconds, 72°C for 30 seconds, 35 cycles, 72°C for 5 minute, and 4°C storage.

Agarose Gel Electrophoresis
Once PCR was completed, samples were loaded on 1% agarose gels for viewing of
amplication products. To constitute these gels, 1.2 g of agarose powder was mixed with
120 ml of 1X Tris Acetate Buffer (40 mM Tris Base, 20 mM Glacial Acetic Acid, and 1

rnM EDTA with pH - 8.0) and heated in a microwave for 1.5 minutes (mixing every 15
seconds to dissolve agarose powder). Ethidium bromide (7.5 p1) at a concentration of
5 pg/pl is added to the gel mixture. The mixture was then poured into a plastic tray,
sealed with a casting tray containing a 25 well gel comb, and the gel was allowed to

polymerize at room temperature. The comb was then removed and the plastic tray, along
with the agarose gel, was transferred to a horizontal electrophoresis chamber containing
Tris Acetate Buffer, needed for optimum DNA mobility. Loadng buffer (2 pl) was then
added to 20 p1 of each sample containing PCR products and each samples was loaded
into a well of the agarose gel. Once the lid of the electrophoresis chamber was closed, 80
rnA current was applied to the gel for 30 minutes, allowing the PCR products to migrate
towards the positive electrode (care is taken to make sure that the products migrate
towards the cathode). The DNA of each sample was then briefly visualized on an
ultraviolet transluminator.

Gel Purification of PCR Products
DNA band were carefully excised from an agarose gel using a scalpel and each band was
placed in a 1.5 ml centrifuge tube. Buffer QG (300 pl), containing guanidine thiocyanate,
was added to gel slice to facilitate melting of the agarose gel when incubated at 60°C for
10 minutes. The gel containing the DNA band was vortexed every three minutes during
heating until the gel was completely dissolved. Once the gel melted, 100 p1 of
isopropanol was added to the melted gel mixture, which ultimately allows binding of the
DNA to the column. Next, the mixture was transferred to the mini column in a centrifuge
tube, which served as a filtering device for elution of the DNA from the melted gel
mixture, followed by brief centrifugation at maximum speed. The eluted gel mixture was
then &scarded and the columns were placed back in collection tubes. To wash the bound
DNA, 0.75 ml of Buffer PE (containing ethanol) was added to the mini columns, and the
columns were incubated at room temperature for 2 minutes, and then centrifuged at

13,0000 rpm speed for 1 minute. Again, the flow-through was discarded and columns are
placed back in collection tubes and centrifuged at maximum speed for 1 minute to
eliminate any residual ethanol from the Buffer PE. Once the gel mixture has completely
filtered through the column and the DNA was washed free of contaminants, the mini
columns were then transferred to a clean 1.5 ml collection tube and a 40 p1 of 10 rnM
Tris-HC1, pH 8.5 was added to the center of the column membrane, incubated for 1
minute at room temperature, and centrifuged at maximum speed for 1 minute. This final
step allows complete elution of clean DNA from the mini columns into the collection
tube.

Sequences and Analysis of PCR Products
An aliquot (10 ng) of each sample was sequenced using 2 p1 of 5 uM Primers.
Sequencing was done at the DNA core lab at the Medical College of Virginia and
SeqWright and Fisher Scientific Laboratory, and Single Nucleotide Polymorphisms were
detected using the CodonCode Aligner computer program

Chapter 3
RESULTS

Preparation of RNA from control cell lines
Total RNA was isolated fiom the three control cell lines using the Trizol method
(Protocol was obtained fiom the Institute of Genomic Research website at
http://pga.tigr.org/soplM019.pdf).Following isolation, 1 pg of total RNA from each cell
line was loaded and run on a 1% denaturing agarose gel to assess its integrity. As was
expected of normal intact RNA, the gel image in Figure 5 displays two distinct bands.
The lower band represents thel8S ribosomal subunit and the upper band represents the

28s ribosomal subunit. The light smear displayed above the upper band and between the
two main bands represents other RNA species, including all of the rnRNAs and also any
minor RNA degradation. The prominent bands on this gel show stable RNA and adequate
RNA concentration for our experiments.

Preparation of RNA from patient samples
For patient samples 1-6, RNA isolation was performed using the Quiagen method which
required considerable less time when compared to the Trizol method (Protocol was
obtained

fiom

the

Institute

of

Genomic

Research

website

at

http://pga.tigr.org/soplMO19.pdf). Residual blood samples ( 1-2 ml) were obtained fiom
the hematology laboratory at the Virginia Commonwealth University Hospital. Samples
were collected in purple top tubes containing ethylenediaminetetraacetic acid (EDTA) to
prevent blood clot formation. Samples were collected fiom patients with a white blood
cell count of at least four, to ensure that sufficient RNA would be available to perform

multiple PCR reactions. Once RNA was extracted from samples 1-6, 1p1 of 50 p1 of total
RNA was loaded and run on a nanochip of .the Agilent 2 100 Bioanalyzer. The Agilent
2100 Bioanalyzer then displayed a virtual gel, which represents a 1% denaturing agarose
gel as it would appear with the same concentration of RNA from each sample. A
representative sample of the virtual gels is illustrated in the upper left hand corner of
Figure 6, with the 150 nglpl ladder shown in the first lane. Like thel% denaturing
agarose gel, the Agilent 2100 Bioanalyzer produces an electropherogram displaying two
peaks, the shorter peak representing the 18s ribosomal unit and higher peak representing
28s ribosomal subunit. The first peak to the far left of each electropherogram represents
the 25-nucleotide marker added to each sample. RNA integrity and concentration was
determined according to the height of each peak, as well as by the amount of small peaks
between the two major peaks. Sample 4, for example, has less RNA degradation than
sample 5, as is evident by the increased amount of smaller peaks that exist between the
two major peaks of sample 5. (See Figure 6).

Gel PCR products of control samples (800 bp and 1 kb)
Once RNA was isolated from the control samples and first stand cDNA synthesis was
performed, amplification of the figs gene was performed using the polymerase chain
reaction (PCR). DNA from the three control samples was amplified into two separate
fiagrnents using two sets of primers. Due to the high GC rich region of the 5' UTR
region of the figs gene, amplification of the gene as a single 1.8 kb fragment was not
feasible. A 24 p1 reaction of the PCR products from each cell line was loaded and run on
a 1% agarose gel for 30 minutes. In Figure 7, the first 800 bp fragment amplified from

each control cell line is displayed in lanes 1-6, with 24 p1 reactions from each cell line
loaded into two wells (for example, 24 p1 PCR products from the CEM cell line was
loaded into lanes 1 and 2). The bands representing the 1 kb fragments for each cell lines
in lanes 7-9 are not as abundant as those representing the 800 bp fragments. Furthermore,
the lower bands in lanes 7-12 represent primer dimer formation, which show decreased
primer specificity for the DNA templates. However, due to the fact that I loaded 48 p1
reaction for each cell line (24 pl in each well), I had sufficient PCR products for
sequencing.

PCR and Sequencing primers used for 800 bp and 1 kb fragments
The primers used for amplification and sequencing of the two fragments of the control
samples are shown in Figure 8. Two sets of primers were used for amplification and
sequencing of each fragment. The first 800 bp fragment was amplified using forward
primer FOR3, which starts 32 nucleotides upstream of the mitochondnal start site and
ends at nucleotide 3. The reverse primer, MR2 starting at nucleotide 885 and ending at
nucleotide 864 was also used to amplify the first 800 bp fragment. The 1 kb fragment
was amplified using forward primer MF1, which starts at nucleotide 809 and ends at
nucleotide 826. Thus, the sequences of the two PCR fragments overlap by 38 nucleotides.
The reverse primer, RP2 starts at nucleotide 1814 and ends at nucleotide 1837.
Sequencing of the 800 bp fragment was performed using primers For6 and F2lasn.
Primers FORSEQ 1 kb and REVSEQ 1 kb were used to sequence the 1 kb fragment.

Amplification of samples 1-6

Following amplification and sequencing of the two fragments of the control samples,
PCR was then performed on patient samples 1-6. Figure 9 displays the PCR products of
the first 800 bp fragment of samples 1-6. Again, 24 pl of PCR product from each patient
sample was loaded into 2 separate wells. Sample 2 was loaded into 3 separate wells
following repeated PCR. Primer dimers (low molecular weight bands formed on the
bottom of the agarose gel) were removed during gel purification. The patient samples
proved to be more difficult than the control samples. Because human peripheral blood
cells have a limited amount of the fpgs rnRNA, I first experienced difficulty amplifLing
the gene in 2 fragments, then I experienced further difficulty sequencing the PCR
products. Before we began this project, we anticipated some dificulty obtaining
sufficient fpgs RNA from human peripheral blood. We then decided to amplifj the f'pgs
gene into 3 fragments with the first fragment at 465 nt, the second at 964 nt and the third
at 615 nt in length. Six primers were designed for PCR and 4 primers were designed for
sequencing (See Figure 11). This solved the PCR amplification problem, as well as the
sequencing problem. An example of a good versus poor sequencing run is illustrated in
Figure 10.

Amplification of 465 bp fragment of the fpgs gene
Once I began amplification of thefigs gene into three fragments, I obtained better results.
Figure 13 is an image of the most upstream 465 bp PCR product from samples 1-13. An
aliquot of 10 pl reactions was loaded on to the 1% agarose gel and 80 mA of current was
applied to the gel for 30 minutes. While some of the PCR products produced sharp
bands, others such as samples 1 and 9 were later repeated to obtain a greater

concentration of PCR products. Sequencing of the PCR products was performed using
reverse primer, REVSEQSOO, as illustrated in Figure 11.

Amplification of the 964 bp fragment
The 964 bp fragment of the fpgs gene was amplified using forward primer, FORNEW
and reverse primer REVNEW. Sequencing was performed using MF1 primer and RMD
primer. Figure 14 is an illustration of the middle 964 bp fragment of samples 1-18,
loaded and run on the 1% agarose gel following PCR. Primer dimers are removed during
gel purification. PCR products of samples, such as sample 3 and 5, were later repeated to
obtain a greater amount of product needed to obtain good sequencing results.

Amplification of downstream 615 bp fragment
Figure 15 displays the downstream 615 bp PCR product of samples 1-8, loaded and run
on the 1% agarose gel. This fragment of the fpgs gene was amplified using forward
primer FPGS RP2 and reverse primer RP2. Sequencing was performed using reverse
primer RP2. Despite the primer dimers that formed in each PCR reaction, we were able
to obtain sufficient amount of the PCR products for sequencing. Again, primer dimers are
removed during gel purification.

Fig 5. RNA of all 3 control cell lines
Total RNA (1 pg) of the three control cell lines, CEM, MCF-7, and WiDr, were loaded
and run on a 1% denaturing agarose gel1 at 80 mV for 30 minutes. Upper bands represent
18s ribosomal RNA subunit and lower bands represent 28s ribosomal RNA subunit. The
appearance of 2 dstinct bands shows intact stable RNA.

CEM

MCF-7

Fig. 5

Fig 6. Ribosomal RNA subunits of samples 1 - 6 displayed by Agilent 2100
Bioanalyzer
Electropherogram display of peaks representing 18s and 28s ribosomal RNA subunit of
total RNA from patient samples 1- 6. The first peak of each electropherogram represents
an aliquot of marker that was loaded into each sample. The lower peak represents the 18s
ribosomal RNA subunit and the higher peak represent the 28s ribosomal RNA subunit.
The smallest minor peaks shown between the 18s and 28s peaks represent any RNA
degradation in the samples. The image below is an illustration, displayed by the Agilent
2100 Bioanalyzer, of a virtual denaturing gel of total RNA from samples 1-6. The left
most lane represents the 150 ng/p1 ladder and lanes 1-6 represents samples 1-6. The
ladder has 6-7 peaks of different sizes, which calibrates the instrument, allowing correct
measurement of the 18s and 28s ribosomal RNA peaks in each samples.

Fig. 6

Fig 7. PCR product of control cell lines (800 bp and 1 kb)
A Display of the 800 bp and 1 kb PCR products of control cell lines, CEM, MCF-7, and

WiDr is shown in figure 7. The 1 kb ladder (8 p1) was loaded into the first lane and the
800 bp PCR products of the three control lines were loaded into lanes 7 - 12. The low

molecular weight bands formed at the bottom of the agarose gel illustrate primer dimers
formed during PCR.

Lane L = Ladder
Lanes 1,2 = CEM (800 bp)
Lanes 3,4 = MCF-7 (800 bp)
Lanes 5,6 = WiDr (800 bp)
Lanes 7,8 = CEM (1 kb)
Lanes 9,10 = MCF-7 (1 kb)
Lanes 11,12 = WiDr (1 kb)

Fig. 7

Fig 8. Primers used for PCR and sequencing of two fragments of the control
samples
A set of primers were used for sequencing of the 800 bp and 1 kb fragments of the figs

gene. The 800 bp fragment was amplified using forward primer FOR3 and reverse
primer MR2. The 1 kb fragment was amplified using forward primer MFI and reverse
primer RP2. A separate set of primers was used to sequence the 800 bp and 1 kb PCR
products of the figs gene. The 800 bp fragment was sequenced using forward primer
For6 and reverse primer F2 lasn. The 1 kb fragment was sequenced using forward primer
FORSEQ 1 kb and reverse primer REVSEQ 1 kb.

Primer

Sequence

Reverse or Forward

Position in Sequence

800 bp fragment
For3
S'GCCGGGGGCGCCGGGACTATG 3'
MR2
5' CTCTATACCTGTGCCGATGC 3'

Forward
Reverse

-32-3
864-885

1 KB fragment
MF 1
5' CCAGCAGATCTCATGTC 3'
RP2
5' GCACCTAGTATGTAAGTTCATGG 3'

Forward
Reverse

809-826
18 14-1837

Sequencin~primers:
800 bp fragment
For6
5' CCGAGCATGGAGTACCA 3'
F2 lasn
5' GGTACAGTTCCATGGCTTCC 3'

Forward
Reverse

121-137
228-247

1 KB fragment
FORSEQ 1 kb
REVSEQ 1 kb

Forward 132 1- 134 1
Reverse 1361-1381

5' AACCTGACAGAGGTGTCATCC 3'
5' CCAGTGTCACTGTGAAGTTC 3'

Fig. 8

Fig 9. PCR products of samples 1-6 (800 bp)

The 800 bp PCR fragments from samples 1 - 6 were loaded and run on 1% agarose gel
at 80 mV for 30 minutes. The 1 kb ladder (8 p1) was loaded into the first lane and 24 p1
of the 800 bp PCR products of each sample was loaded into 2 separate wells in lanes 1 10. Sample 2 was repeated and loaded into three separate wells. The negative control
was loaded into the second lane of the bottom gel (lane N).

Lanes 1,2 = sample 1 (800 bp)
Lanes 3,4 = sample 3 (800 bp)
Lanes 5,6 = sample 4 (800 bp)

Lanes 7,8 = sample 5 (800 bp)
Lanes 9,10 =sample 6 (800 bp)
Lane L = Ladder

Lane N= negative
Lanes 1 1,12,13 = sample 2 (800 bp)

Fig. 9

Fig 10. Good and poor sequencing results of 1 kb fragment of samples 1-6
The top figure is an illustration of a chromatogram of the 1 kb PCR product of one
sample that was poorly sequenced. The lower chromatogram figure shows an example of
a successful sequencing run performed on the 800 bp PCR product of one of the samples.
In the bottom chromatogram, the peaks of the raw data are distinguishable in height and
color. Unlike the top chromatograrn, the program was able to successfully label each
peak with the appropriate nucleotide. Furthermore, there is little to no background peaks
in the bottom chromatograrn, which eliminates any chance of misinterpreting sequencing
errors for a single nucleotide polymorphism.

Fig. 10

Fig 11. Primers used for PCR and sequencing of the three fragments of thefpgs gene
Three sets of primers were used for sequencing of the 465 bp, 964 bp, and 615 bp
fragments of thefpgs gene. The 465 bp fragment was amplified using forward primer
FOR3 and reverse primer RevSeq800. The middle 964 bp fragment was amplified using
forward primer FORNEW and reverse primer REVNEW. The downstream 615 bp
fragment was amplified using forward primer FPGS RP2 and reverse primer RP2. A
separate set of primers was used to sequence the three PCR fragments of the figs gene.
The upstream 465 bp fragment was sequenced using reverse primer RevSeq800 and the
middle 964 bp fragment was sequenced using forward primer MF1 and reverse primer

RMD. The downstream 615 bp fragment was sequenced using reverse primer RP2.

PCR Primers
Primer
Sequence
Reverse or Forward
Position in Sequence
Upstream 465 bp
For3
GCCGGGGGCGCCGGGACTATG
Forward
-32-3
RevSeq800 TGAAGAGCTCAGGACTGATGG
Reverse
437-458
Middle 964bp
FORNEW
AAGCTATGGCCTGAAGACGGGATT
REVNEW
AGGGCAGAAGACGGCATAGTCAAA

Forward
Reverse

657-380
1297-1320

Downstream 615 bp
FPGS RP2
GTTCGAGTCTTGCTCTTCAATGCTAC Forward
RP2
GCACCTAGTATGTAAGTTCATGG
Reverse

1322-1347
1814-1837

Sequencing Primers
Upstream 465 bp
RevSeq800 TGAAGAGCTCAGGACTGATGG

Reverse

437-458

Middle 964 bp
h4F1
CCAGCAGATCTCATGTC
Forward
RMD
GTTCGAGTCTTGCTCTTCAATGCTAC Reverse

809-826
969-990

Downstream 615 bp
RP2
GCACCTAGTATGTAAGTTCATGG

1814-1837

Fig. 11

Reverse

Fig 12. Diagram of primers used for amplification of the gene into 2 and 3 fragments
A schematic of the PCR primers used to amplify the fpgs gene into 2 and 3 fragments is
illustrated in Figure 12. The top figure represents the 1.8 kb cDNA construct of the figs
when amplified into 2 fragments, an 800 bp and 1 kb fragment. The primers used to
amplifjl the 800 bp fragment are forward primer For3 (shown in red in the top figure) and
reverse primer MRl (also shown in red in the top figure). The 1 kb PCR fragment was
amplified using forward primer MF1 (shown in blue in the top figure) and reverse primer
RP2 (also shown in blue in the top figure). Following unsuccessful amplification of the
figs gene into 2 fragments using patient samples, attempts were made to amplifL the gene

into three fragments. The bottom figure represents the 1.8 kb cDNA construct amplified
into 3 fragments, a 465 bp, a 964 bp and downstream 6 15 bp fragment. The primers used
to amplify the upstream 465 bp fragment are forward primer For3 (shown in red in the
top figure) and reverse primer Revseq800 (shown in red in the bottom figure). The 964
bp PCR fragment was amplified using forward primer FORNEW (shown in blue in the
bottom figure) and reverse primer REVNEW (also shown in blue in the bottom figure).
The primers used to amplify the downstream 615 bp fragment are forward primer
FPGSRP2 (shown in brown in the bottom figure) and reverse primer RP2 (shown in
brown in the bottom figure).

OverIappine PCR rimer sequences of the 2 fragments

PCR primer sequences of 3 framents.
Overlart~in~

Fig. 12

Fig 13. Example of upstream 465 bp PCR products
The 465 bp PCR fragments from ten of the samples were loaded and run on 1% agarose
gel at 80 mV for 30 minutes. The 1 kb ladder (8 p1) was loaded into the first lane and 24
p1 of the 465 bp PCR products of samples 1 - 13 were loaded into each well in lanes 1 -

13. Sample 26 and 38 were later repeated to obtain a higher concentration.

Lane 1 =
Lane 2 =
Lane 3 =
Lane 4 =
Lane 5 =

sample 25
sample 26
sample 27
sample 28
sample 29

Lane 6 = sample 30
Lane 7 = sample 3 1
Lane 8 = sample 32
Lane 9= sample 38
Lanes 10 = sample 39

Fig. 13

Lane 1 1 = sample 40
Lane 12 = sample 4 1
Lane 13 = sample 42
Lane L =Ladder

Fig 14. Example of 964 bp PCR products
964 bp PCR fragments from 18 of the samples were loaded and run on 1% agarose gel at
80 mV for 30 minutes. The 1 kb ladder (8 pl) was loaded into the first lane and 24 p1 of

negative control was loaded into the second lane. The 964 bp PCR products of these
samples (24 pl) were loaded into each well in lanes 1 - 18. Sample 66 and 68 were later
repeated to obtain higher concentrations.

Lane N =
Lane 1=
Lane 2 =
Lane 3 =
Lane 4 =
Lane 5 =
Lane 6 =

Negative control
sample 6 1
sample 62
sample 66
sample 67
sample 68
sample 72

Lane 7 = sample 73
Lane 8 = sample 75
Lane 9 = sample 76
Lane 10 = sample 80
Lane 1 1 = sample 82
Lane 12 = sample 83
Lane 13= sample 86

Fig. 14

Lane 14 = sample 87
Lane 15= sample 88
Lane 16 = sample 89
Lane 17 = sample 90
Lane 18 = sample 9 1
Lane L = Ladder

Fig 15. Example of downstream 615 bp PCR products

The downstream 615 bp PCR fragments from eight of the samples were loaded and run
on 1% agarose gel at 80 mV for 30 minutes. The 1 kb ladder (8 11) was loaded into the
first lane (lane L) and 24 p1 of the 6 15 bp PCR products of each sample was loaded into
each well in lanes 1 - 8. All eight samples were successfully amplified.

Lane 1 =
Lane 2 =
Lane 3 =
Lane 4 =
Lane 5 =

sample 44
sample 45
sample 47
sample 49
sample 5 1

Lane 6 = sample 52
Lane 7 = sample 53
Lane 8 = sample 54
Lane L = Ladder

Fig. 15

Chapter 4

Detection of Single Nucleotide Polymorphisms in Fpgs Gene
Use of the CodonCode Aligner to detect SNPs
The CodonCode Aligner is a multifunctional user-friendly software program designed by
the CodonCode Corporation. This program is capable of aligning sequences, editing
sequences, and detecting mutations. Once we obtained a license for use of this program,
sequences were imported and aligned as traces into the program folder. Once sample
traces were aligned, we clipped the beginning and end of the sequences to remove
undecipherable peaks (See Figure 10 for an example of unreadable sequences). The
program also allowed viewing of the sequences in reverse complement forms, which
optimized sequence analysis of the reverse strand. Upon alignment of the sequences, the
program determines the consensus sequence, which it &splays at the bottom of the
screen, labled contig 1 (See Figure 16). We then instructed the program to detect
mutations beginning at a predetermined start codon and ending at a predetermined stop
codon of the sequence (users may determine where to begin and end sequence analysis).
Following sequence analysis, the CodonCode Aligner program tagged various areas of
each sequence indicating sequence quality and mutations types, such as single nucleotide
polymorphisms (See figure 16). The tags, which are color coded, can also be modified in
intensity and color by the user (See figure 16). If a sequence differed by one or more
nucleotides from the consensus sequence, the program tagged that base in the consensus
sequence, labeled contigl in figure 16 (See figure 16). In Figure 16, for example, the
consensus base is A/A, which is highlighted in red in sequence 29C and the consensus

sequence (contig 1). In the bottom sequence labeled 40C, however the GIG homozygote
allele is expressed at this position, which the program highlights in the consensus
sequence using a red tag. So essentially, one method of detecting a SNP using this
program was to scan the consensus sequence for tagged bases. Another method of
detected SNPs was to scan every single sequence for tags and then analyze every tagged
area for possible SNPs. Though extremely tedious and time consuming, ths method
proved to be the most effective form of sequence analysis. The program not only tagged
mutations and poor quality peaks, but it also tagged every position where peaks were not
as high as adjacent peaks or where peaks were not equidistance to adjacent peaks. For
this, we spent a great deal of time analyzing tagged areas of the sequences that were
ultimately accepted as normal sequence. It was important to analyze all tagged areas to
ensure that no SNPS were overlooked. Figure 23, for example, shows an important SNP
at nucleotide 1334 that sequestered in a poor quality region of the sequence. Following
sequence analysis, repeated PCR, and repeated sequence analysis, we eliminated a large
number of false positive SNPs. An example of a false positive is illustrated in Figure 17.
This apparent SNP was not observed in repeat sequences over this region. Ultimately, it
was determined that a SNP was real if the base at the position where two nucleotides
were observed, decreased in height when compared to the base at the corresponding
position in the wild type sequence. For example, in Figure 18 base G in the A/G SNP at
nucleotide 64 deceased in height by approximately one-half when compared to the GIG
wild type sequence below. Similarly Figure 19 base G in the GIA SNP at nucleotide 123
deceased in height when compared to the G/Gwild type sequence.

SNPs Detected
Due to the fact that the fpgs coding sequence was amplified in three pieces, some
fragments were more successfully amplified in some samples than in others. For
example, 88 samples were successfully amplified for the first 465 nucleotides of the @gs
gene, while 78 samples were successfully amplified for the middle fragment spanning
964 nucleotides. The last 615 base pair fragment was successfully amplified in 85 of the
samples. For the remaining 15-20 samples, PCR or sequencing was unsuccessful due to

RNAI DNA instability or limited amount of RNA availability (all samples are unique to
each patient and were available in very limited supply). Following sequencing of
approximately 78-88 samples, polymorphic sites were found at nucleotides 64, 123,253,
423, 1334 and 1781 (See Figure 16-21). These SNPs are summarized in table 1.
Sequencing of the first 465 nucleotides was performed on 88 total samples. Of the first
PCR fragment sequenced, in a total of 88 samples, 48 samples express a heterozygote
GIA genotype at nucleotide 64 (- 55 %), 1 sample expressed the homozygote A/A at this
site (- 1 %), and the remaining samples expressed the homozygote GIG genotype at this
position (- 44 %). At nucleotide 123, 6 samples (samples 12, 45, 88, 90, 97, 99)
expressed the heterozygote GIA genotype (- 7 %), and one sample (sample 74) expressed
the homozygote A/A allele at this site (- 1 %), and 81 (- 92 %), samples express the wild

type GIG allele. Of the 88 samples sequenced, only one sample (sample 80) expressed a
heterozygote C/T allele at nucleotide 253 (- 1 %). SNPs that were detected in less than
10 % of the samples were confirmed by repeated amplification and repeated sequencing
cDNA from both directions. For the second fragment, at nucleotide 423, two samples (32
& 97) expressed a heterozygous CIG allele (- 3 %), while the remaining samples

expressed a homozygous C/C allele (- 97 %). At nucleotide 1334, one sample (26)
expressed TIC allele while the remaining samples were C/C at this site (- 1 %). Again,
this SNP was found by reamplifLing and resequencing cDNA from this sample. The
homozygous change at nucleotide 64 encodes a conservative amino acid change from a
valine to isoleucine. The G123A change expressed in six of the samples produced no
change in the proline at this codon. Similarly, at nucleotide 423 the SNP observed was
silent, that is, both wild type codon (CGC) and the mutant codon (CGG) encoded the
amino acid, arginine. At nuclotide 253, however, a C to T base change produced a change
from arginine to tryptophan. The heterozygote TIT allele at nucleotide 1334, expessed in
the&

gene of sample 26, caused a valine to alanine amino acid change. The G1781A

SNP was detected downstream from the stop codon in sample 40 (- 1 %). A summary of
these results is displayed in Table 1.

Fig 16. Example of tagged SNPs in consensus sequence.
A portion of the downstream 6 15 bp sequence of sample 29 and 40 is displayed in Figure
16. The consensus sequence of this portion of the gene is also displayed at the bottom of

the figure, labeled Contigl. Because the two sequences of samples 29 and 40 differ by
one nucleotide at the position highlighted by the program in red, the program also
highlights that nucleotide position in the consensus sequence displayed at the bottom of
the screen (shown by the arrow).

~4
ETGGGAGCT

29C-fwd GCACCTGGTG GGIWGTCC TGAAGCTGCT GGAGCCCGCA CTWCCCAGT AGCCMGGCC CGMTGAR GGTGGGAGCT T(XWAEP

4OC-fwd GCACCTGGTG G@WTGTCC TGARGCTGCI GGAGCCCW CTGTCCCAGT AGCCAAGGCC
1451

1461

1471

1481

1491

1501

WCACACCf

1511

521

h
1

Contigl GCACCTGGTG GGTGTGTCC TGAAGCTGCT GGAGCCCGCA CTGTCCCAGT AGCCAAGGCC CGGGGTTGAA GGTGGGAGCT TCCCACACCT

Fig. 16

Fig 17. Example of false positive SNPs
False positive SNPs fkequently appeared during sequence analysis. This false positive
shown in the top chromatogram and highlighted in green by the Codoncode Aligner
program originally appeared to be a SNP because of the double peak at this position
(shown by the arrow) as well as the lack of background sequencing error in adjacent
peaks. This SNP, however, did not appear during repeated sequence analysis of repeated
PCR products.

-

4 T G C C GT

GTGCGCA

150

\ T G CCGTGCGCA
10
150

I

Fig. 17

Fig 18. SNP 64 AIG Valine/Isoleucine
SNP 64 is highlighted by the Codoncode Aligner program in the top chromatogram.

There are no background sequencing errors, which optimizes sequence analysis and
accuracy.

The lower three chromatograms have a single peak at nucleotide 64,

representing either the homozygote A/A or GIG Allele. The peaks of these lower four
chromatograms are approximately double the height of the peak in the chromatogram of
the heterozygote GIA SNP.

1. Heterozygote GIA

X G C A T A A CGA

0
2. Homozygote A/A

~1

:OOC

T A A CGA

I
3. Homozygote GIG

/
4. Homozygote GIG

Fig. 18

Fig 19. SNP 123 A/G Prolineff roline
SNP 123 is highlighted in the first three chromatograms below, while the wild type
homozygote GIG allele is displayed in the bottom chromatogram. The homozygote A/A

S N P is shown in the second chromatogram. Again, there are no background sequencing
errors, optimizing sequence analysis and accuracy, and the peaks of the homozygote
alleles are higher than the peaks of the heterozygote alleles.

/
1. Heterozygote GIA

t
2. Homozygote A/A

3. Heterozygote G/A

/
4. Homozygote GIG

Fig. 19

Fig 20. SNP 253 C/T Argininemryptophan
SNP 253, which caused an arginine to tryptopan amino acid change, is displayed in

chromatogram 1. This SNP caused a C to T base change in the ACG nucleotide triplet
coding for the aarginine amino acid. Chromatogram 2 and 3, in the figure below, shows
the homozygote TIT wild type allele.

Fig 21. SNP 423 CIG ArginineIArginine
Chromatograms 1 and 2 in the figure below show SNP 423, which caused a C to G base
change in the CGC codon. The wild type homozygote CIC allele is displayed in the
chromatogram 3. The heterozygote C to G base change did not change the arginine
amino acid coded by the CGC nucleotide triplet.

c
1. Heterozygote C/G

'

i

c

y

C~
AATGG
50

1
2. Heterozygote CIG

T C C G C A T C A ATGG

40

I

50
3. Homozygote CIC

Fig. 21

Fig 22. SNP 1334 C/T ValineIAlanine
SNP 1334, which caused a valine to alanine amino acid change is displayed in

chromatogram 1. This SNP caused a C to T base change in the CTG nucleotide triplet
coding for the valine amino acid. Chromatogram 2, in the figure below, shows the
homozygote TIT wild type allele and chromatogram 1 shows the homozygote CIC allele.

Fig 23. SNP 1781 A/G
SNP 1781 in figure 23 resulted n a homozygote A to G base change. The heterozygote
A/A alleles are displayed in chromatograms 1 and 4, and the wild type A/A alleles are

displayed in chromatograms 2 and 3. Because this SNP is located downstream fiom the
stop codon, no amino acids are translated by the ribosomal RNAs.

Fig. 23

Table 1.
Detected Human fpgs SNPs
nt

SNP

Codon Change

Amino Acid Change

64

AIG

ATA > GTA

Isoleucine> Valine

123

GIA

CCG > CCA

Proline (no change)

253

C/T

ACG > ACG

Arginine > Tryptophan

423

C/G

CGC > CGG

Arginine (no change)

1350

CIG

AAC > AAG

Asparagine > Lysine

1781

GIA

GGA > GAA

---

Table 2.

Humanfpgs SNPs of the NCBI database
Entry number

Comment

Sequence

TAAG[M]TGCA

Not found on the FPGS genomic locus by
Blast search
Random sequence

437 V>D Checked in 209
samples,
never
found. Sequencing
error
htron
Intron 15
Intron

GcGG[A/C]GTAA

Exon 1

CTAC[-IAIAAAA

Intron 14

ATAG[CKJTGGG

Intron 16

ACAT[CmTCAG

Intron 10

AATA[AIG]GGTG

Intron 5

TTGC[CWCTAG

Tntron 1

gcac[Wag

Intron 5

CGGC[A/G]TAAC

Exon 1

aatt[A/G]ttag

Intron

2 1 G>G Random sequence

22 I>V

nt 64 (again)

rs10118903
gene by Blast

tctc[-/AA]aaaa

Intron 15

gg=[NG]aggca

Intron 5

WiP[~Igccg

Intron 5

g5~[NGIaagc

Intron 5

CCAG[A/G]AGTG

Won 1

TGGT[CfqGGTG

?

l'TTT[G/TlGGTT

Intron 12

gtct[C/Tltaca

Intron 15

@gt[G/Tlm

Intron 15

ACCT[NG]CTAT

Intron 1

~@gw']@

Intron 15

cact [C/T]gaac

Intron 9

GGGC [A/G]GGGC

Intron 13

tW-/Tlgaga

Intron 5

ATAC[A/C]CATT

Exon 15

Not found on the FPGS
analysis

Confirmed
in
209
individuals. AAIAGIGG =
.885/.0911.024

Confirmed in
354 samples.
AAIACICC =
.065/.234/.333
The remaining
.367allelic
frequencies
was
unspecified
(see
NCBI
Database)

294 P A

AAGG[CR]TGGG

Confirmed. 23
samples
AAIAG
.957/.043

Intron 2
Intron 5

CCTT[CqTGGG

exon 15

GATA[A/G]CAGA

Intron

Checked in 204 samples.
No SNP found at this nt.
Error in reference sequence

ATCA[G/T]GGGT

Intron 1

Checked in four studies,
three had 100 % CCs in all
30 samples; the other had
100 % GG in all 47
samples

GCC A[A/G]GAGG Exon 15

3'-UTR. Checked in 42 1 individuals.
AA/AG/GG = .221/ .480/
.299

DISCUSSION
Previous studies by Barredo, J et a1 showed that while substantial levels of thefigs gene
was expressed in lymphoblasts from patients with acute lymphoblastic leukemia, no
expression of this gene was detected in circulating granulocytes, erythrocytes, and
lymphocytes (23). In this experiment, however, we were able to successfully detect RNA
expression in monocytes and lymphocytes. The discrepancy in both these results has
much to do with the difference in techtuques being used to detectfigs expression. While
Barredo, J et a1 used a protein enzyme assay technique to detect FPGS activity, in this
experiment we first extracted the RNA from the mononuclear cells then used Polymerase
Chain Reaction to amplify the gene. PCR is a much more sensitive technique than an
enzyme assay technique for detecting RNA expression. With as little as 1 pg of DNA, we
were able successfully amplify and sequence 85 % of thefpgs gene in the mononuclear
cells of the hurnan peripheral blood. Barredo, J et a1 did not have the benefit of using the
PCR technique for detecting figs RNA expression in mononuclear cells because the
sequence of thefpgs gene, which was required for designing primers, was not yet known.
With the advantages of PCR and the availability of thefpgs gene sequence we were able
to detect and confirm, by repeated testing, six single nucleotide polymorphisms expressed
in the fpgs gene, of the peripheral blood, of 85 normal human subjects. These single
nucleotide polymorphisms are located in a variety of different regions of thefigs gene.
One SNP was detected in the mitochondnal leader sequencing, another was detected
downstream of the stop codon, whle the other four SNPs were detected within the
cytosolic coding sequence of the protein. The only frequently observed SNPs in the

coding region were in the mitochondnal leader sequence. SNPs downstream of the
cytosolic start methionine were rare.
The first SNP ( N G ) at nucleotide 64 caused a base change in the first position of the
codon, resulting in a valine to isoleucine amino acid change. This SNP, which was
previously reported by Freemantle et al. was detected in a majority of the samples
(49/88). The valine to isoleucine amino acid change, caused by a conservative point
mutation, is expected to have little to no effect on the structure and function of the
protein. Furthermore, this SNP is located in a region upstream of the cytosolic start site,
and so is not expected to significantly affect catalytic function, although it might well
affect the efficiency of mitochondnal entry.
The second most frequently detected SNP, which was expressed in the third position of
the codon at nucleotide 123, did not change the proline amino acid at that position of the
polypeptide. Six of the samples expressed the GIA heterozygote allele at nucleotide 123,
while only one sample expressed the homozygote AIA allele. Because this SNP did not
change the amino acid, no change in protein structure and function would be expected.
Similarly, SNP 423 also caused a base change in the third position of the codon, which
did not change the arginine amino acid located at that position in the growing
polypeptide. The remaining three SNPs, however, alter the codon sequence, which
resulted in a nonconservative change in the amino acids. One of these SNPs, C253T,
caused a base change at nucleotide 253 in the first position of the codon, replacing an
arginine amino acid with tryptophan, a more bulky amino acid.

This amino acid

conversion, which was detected in one of the 88 samples, might affect the chemical
nature of ,the enzyme, and would presumably alter the enzymatic activity of the fpgs

protein. Similarly, SNP T1334C, which caused a base change at the second position of
the codon, resulted in a valine to alanine amino acid change in the polypeptide chain.
The final SNP was detected at position 1781 (GIA) at the second position of the
nucleotide triplet, falling outside of the reading fiame of the fpgs gene. Normally amino
acids translated outside of the reading frame of the gene do not play a role in protein
function, however, SNP 1781 might affect the stability of the mRNA or the efficiency of
polyadenylation of the message.
There have been limited studies done on polymorphisms in the human fpgs gene, and
very little is known about the effects of any polymorphisms in the gene that may alter
clinical response to antifolate therapy. The next major step of this project it to analyze
the effects of polymorphisms detected in the fpgs gene on response rate to cancer
chemotherapy. Cells, which are mutant for the fpgs gene, will be transfected with fpgs
gene construct expressing known polymorphic sites. These cells with then be observed
for change in enzymatic activity of the gene.
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